Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

  • John Hayslip1,
  • Uzair Chaudhary1,
  • Mark Green1,
  • Mario Meyer1,
  • Steven Dunder1,
  • Carol Sherman1,
  • Shanta Salzer1,
  • Andrew Kraft1 and
  • Alberto J Montero1Email author
BMC Cancer20077:221

https://doi.org/10.1186/1471-2407-7-221

Received: 10 July 2007

Accepted: 03 December 2007

Published: 03 December 2007

Abstract

Background

COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors, such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in tumor growth. The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortezomib in combination with celecoxib in patients with advanced solid tumors.

Methods

Patients received escalating doses of bortezomib either on a weekly schedule (days 1, 8, 15, 22, and 29 repeated every 42 days) or on a twice-weekly administration schedule (days 1, 4, 8, and 11 repeated every 21 days), in combination with escalating doses of celecoxib twice daily throughout the study period from 200 mg to 400 mg twice daily.

Results

No dose-limiting toxicity was observed during the study period. Two patients had stable disease lasting for four and five months each, and sixteen patients developed progressive disease.

Conclusion

The combination of bortezomib and celecoxib was well tolerated, without dose limiting toxicities observed throughout the dosing ranges tested, and will be studied further at the highest dose levels investigated.

Trial registration number

NCT00290680.

Background

The ubiquitin-proteasome pathway plays an important role in cell cycle regulation, neoplastic growth, and metastasis [1, 2]. At the heart of this degradative pathway is the 26S proteasome, an adenosine triphosphate-dependent protease. The 26S proteasome consists of a core 20S particle, which contains the catalytic proteinase functions, symmetrically bound to two copies of the regulatory 19S particle. Proteolytic removal of damaged or misfolded ubiquitinated proteins is an important part of the homeostatic function of the 26S proteasome. Additionally, the 26S proteasome is vital in degrading regulatory proteins that govern cell cycle, transcription factor activation, cell trafficking, and apoptosis.

The ubiquitin-proteasome pathway is responsible for the ordered degradation of several regulatory proteins necessary for cells to progress through the cell cycle. The tumor suppressor p53, which acts as a negative regulator of cell growth, is one example of targeted ubiquitin-proteasome mediated degradation. p53 is required for the transcription of a number of genes involved in cell cycle control and DNA synthesis. p53 also plays an important role in apoptosis induced by cellular damage [3]. Cyclins and the cyclin-dependent kinase inhibitors p21 and p27 are also regulated by proteasome-dependent proteolysis [4]. Both p21 and p27 can induce cell cycle arrest by inhibiting the cyclin D-, E-, and A-dependent kinases [5].

The ubiquitin-proteasome pathway also plays an important role in transcriptional regulation. Nuclear factor-κB (NF-κB) is a key transcription factor, whose activation is regulated by proteasome-mediated degradation of the inhibitor protein I kappa B alpha-associated protein kinase (IκBa) [4, 5]. Cell adhesion molecules such as E-selectin, ICAM-1, and VCAM-1, are regulated by NF-κB and are involved in the development of angiogenesis and tumor metastasis in vivo [4]. During metastasis, these molecules direct the adhesion and extravasation of tumor cells from the vasculature to distant tissue sites within the body. Additionally, many cell types require NF-κB to maintain cell viability as an anti-apoptotic controlling factor or growth factor [4]. Inhibiting NF-κB activation by stabilizing the IκBa protein potentiates apoptosis of cancer cells to environmental stresses and cytotoxic agents.

Another enzyme recently targeted for cancer prevention and treatment, cyclooxygenase (COX)-2, has garnered increasing interest due to substantial epidemiologic, experimental, pathologic, and clinical evidence suggesting that nonsteroidal anti-inflammatory drugs (NSAIDs) possess anticancer properties [68]. NSAIDs are thought to exert their anti-inflammatory effects by inhibiting prostaglandin synthesis through nonspecific inhibition of COX enzymes. Prostaglandins, in particular prostaglandin E2, appear to be important in oncogenesis due to their effects on cellular adhesion, immune surveillance, and apoptosis [9]. Compared with normal tissues, cancers have been shown to over-express prostaglandins [1017]. In several animal and human models, inhibiting prostaglandin synthesis by blocking COX-2 appears to protect against oncogenesis in many tissue types including: breast, colon, esophageal, lung, skin, and head and neck cancers [6, 7, 1016].

COX-2 is undetectable in most normal tissues; however, it is induced at sites of inflammation by cytokines, growth factors, tumor promoters, and is over-expressed in neoplasia [17]. Several mechanisms have been proposed to explain the role of COX-2 in tumorigenesis, including stimulating cancer cell proliferation, enhancing angiogenesis, and inhibiting apoptosis [18, 19]. In vitro inhibition of COX-2 with targeted molecules is thought to promote apoptosis of cancer cells through inhibition of NF-kB activation [20].

Both COX-2 inhibitors and ubiquitin-proteasome pathway inhibitors down-regulate NF-κB and their combination is an interesting opportunity to explore clinical synergy with these two classes of agents. The ubiquitin-proteasome pathway is involved in NF-κB regulation through its impact on degradation of IκB and release of NF-κB for translocation from the cytoplasm to the nucleus [21]. Inhibition of IκB degradation by proteasome inhibition can limit the actions of NF-κB rendering tumor cells more prone to apoptosis. The combination of the NSAID sulindac and bortezomib was found to be synergistic both in vitro, in colon cancer cell lines, and in vivo, in a xenograft model [22]. Additionally, the COX-2 inhibitor celecoxib has been reported to induce apoptosis independent of its COX-2 effects using NF-κB as a probably target [23]. Consequently, given the relevance of the COX-2 oncogene to numerous solid tumors, clinical evaluation of a COX-2 inhibitor/proteasome inhibitor combination is warranted in patients with solid tumors.

We therefore hypothesized that the combination of the COX-2 inhibitor celecoxib and the ubiquitin-proteasome pathway inhibitor bortezomib is a potentially active clinical combination in the treatment of advanced solid tumors. Therefore, we conducted a phase I study to determine the maximum tolerated dose (MTD) and toxicity profile of bortezomib in combination with celecoxib.

Methods

Patient Selection

Patients with a stage IV histologically proven malignant neoplasm (solid tumor) arising from any primary site with the exception of bone marrow or lymphoid tissue were eligible for this study. Other eligibility criteria included: recurrent or progressive disease after chemotherapy or radiation or chemotherapy or radiotherapy-naive disease that, due to the patient co-morbidities or wishes, is not a candidate for standard treatment, no prior therapy with bortezomib, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, neutrophil count > 1500/mm3, platelets > 100,000/mm3, creatinine < 2.0 mg/dl (or creatinine clearance of > 30 ml/minute), bilirubin < 2 mg/dl, and age > 18 years. Previous radiotherapy was permitted provided that it was completed more than two weeks before enrollment. All subjects provided written informed consent.

The exclusion criteria were as follows: ≥ grade 2 peripheral neuropathy, hypersensitivity to bortezomib, boron, or mannitol, hypersensitivity to any of the COX-2 inhibitors, hypersensitivity to sulfa drugs, hypersensitivity to other NSAIDs, active gastrointestinal ulcer, or history of GI bleeding resulting from prior therapy with NSAIDs, pregnancy, or actively breast-feeding. This study was approved by the institutional review board of the Medical University of South Carolina.

Study Design

This was an open-label, single center, nonrandomized, dose-escalating phase I study utilizing a modified Fibonacci design. Escalating doses of bortezomib were administered as a short IV bolus on days 1, 4, 8, and 11 every 3 weeks or on days 1, 8, 15, 22 and 29 every 6 weeks along with celecoxib orally twice a day. Each cycle was 21 days or 42 days in length depending on the bortezomib administration assignment. The trial did not escalate above 1.3 mg/m2 of bortezomib twice weekly or 1.6 mg/m2 of bortezomib weekly because previously reported single-agent bortezomib trials have reported significant toxicities above these doses [24, 25]. Similarly, celecoxib was not escalated above 400 mg twice daily due to emerging cardiac toxicity data from other trials [26]. Three patients were initially enrolled at each dosing level. If one patient experienced a dose-limiting toxicity, an additional three patients would be accrued to that level. However, if two patients experience a dose-limiting toxicity no further patients would be accrued to that dose level. No maximal number of cycles was pre-specified and patients with stable or responding disease were encouraged to remain on therapy in the absence of significant toxicites. For patients who experienced a dose limiting toxicity (DLT), a dose adjustment was allowed if it was felt that the patient was benefiting from the therapy (responding or stable disease). The dose of each drug in this study is detailed in Table 1.
Table 1

Bortezomib and celecoxib cohort dosing schedules

Cohorts

Bortezomib (mg/m2)

Bortezomib days of administration

Celecoxib (mg PO bid)

Level 1

1.0

1, 8, 15, 22, 29 q42 days

200

Level 2

1.0

1, 4, 8, 11 q21 days

200

Level 3

1.3

1, 8, 15, 22, 29 q42 days

300

Level 4

1.3

1, 4, 8, 11 q21 days

300

Level 5

1.6

1, 8, 15, 22, 29 q42 days

400

Level 6

1.3

1, 4, 8, 11 q21 days

400

Definition of dose-limiting toxicities and maximum tolerated dose

Only dose-limiting toxicities (DLTs) occurring during the first cycle of therapy were used to define the maximum tolerated dose (MTD). DLTs were defined as follows: any documented grade IV granulocytopenia or thrombocytopenia possibly or probably due to protocol therapy, any documented ≥ grade III non-hematologic toxicity (except for grade III nausea or vomiting or diarrhea in the first cycle but controlled to a maximum of grade II with anti-emetic or anti-diarrheal therapy in a second cycle), inability to deliver any chemotherapy on day 8 of cycle 1 because of neutrophil count < 1000/μl or platelet count < 50,000/μl, or the inability to begin a subsequent cycle of chemotherapy within 14 days of the scheduled date due to persisting hematologic or non-hematologic toxicity of greater than grade 1.

Treatment Assessments

Response and progression were evaluated in this study using the international guidelines proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [27]. Baseline evaluations included physical exam, serum chemistries, hepatic function testing, complete blood counts, and computed tomography or magnetic resonance imaging at the discretion of the treating physician. The same imagining modality and laboratory evaluations were completed every two cycles to evaluate for response or progression. Patients underwent a physical exam, serum chemistries, and complete blood count evaluation on the first day of each cycle. Additionally, a complete blood count was required on day 4 of the 21 day cycles or day 8 of the 42 days cycles. Further, complete blood count and serum chemistries were required on day 8 of the 21 day cycles or day 15 of the 42 day cycles. NCI Common Toxicity Criteria Adverse Event version 3.0 criteria were used to grade toxicities.

Results

Patient characteristics

Eighteen patients were enrolled from April 2005 to July 2006. All patients met the entry criteria and were treated in accordance with protocol guidelines. The median age of patients was 62 years and both males and females were well represented. All patients had performance status of 2 or better and patients with a variety of tumor histologies were enrolled (Table 2).
Table 2

Patient characteristics

Patients enrolled

18

Sex

 

   Male

10

   Female

8

Age, years

 

   Median

62

   Range

46–77

ECOG status

 

   0

4

   1

12

   2

2

Cancer Type

 

   Adrenocortical

1

   Colon

2

   Esophageal

1

   Fallopian Tube

1

   Hepatocellular

1

   Leiomyosarcoma

1

   Non-Small Cell Lung Carcinoma

1

   Ovarian

1

   Pancreatic

3

   Renal Cell

2

   Squamous Cell

2

   Transitional Cell

1

   Unknown Primary

1

Previous lines of chemotherapy

 

   0–3

11

   4–6

5

   >6

2

Toxicity and treatment cycles

No dose limiting toxicities were observed during the first cycle of treatment for any patient and the maximal planned dosages were achieved. Creatinine elevation, neuropathy, and fatigue/weakness were the most commonly observed toxicities and a full toxicity report is included (Table 3). From these results, we did not discern specific synergistic toxicities from this combination and dose level six has been selected for the subsequent phase II study. The median number of cycles was two for cohort one, two for cohort two, one for cohort three, two for cohort four, one for cohort five, and two for cohort six. One patient experienced stable disease for six cycles until experiencing diarrhea, thought to be bacterial-induced, and withdrew from the study. All other patients ended treatment due to disease progression and no other patients withdrew or were removed due to toxicities.
Table 3

Incidence of clinically relevant toxicities

Toxicities

Cohort 1

 

Cohort 2

 

Cohort 3

 

Cohort 4

 

Cohort 5

 

Cohort 6

 
 

Toxicity Grade

 

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

Alkaline phosphatase elevation

0

0

0

0

0

0

0

1

0

0

0

0

Anemia

0

0

1

0

0

0

0

0

0

0

0

0

Creatinine elevation

1

0

2

0

0

0

0

0

0

0

0

0

Edema

0

0

0

0

0

0

0

0

0

0

1

0

Hyperkalemia

1

0

0

0

0

0

0

0

0

0

0

0

Hypoalbuminemia

0

0

1

0

0

0

0

0

0

0

0

0

Infection

0

0

0

1*

0

0

0

0

0

0

0

0

Insomnia

0

0

0

0

1

0

0

0

0

0

0

0

Nausea/emesis

0

0

0

0

1

0

0

0

0

0

0

1

Neuropathy

0

0

1

0

0

0

1

0

0

0

0

0

Pruritis

0

0

1

0

0

0

0

0

0

0

0

0

Weakness/fatigue

0

0

1

1

0

0

0

0

0

0

0

0

* Right gluteal and inguinal furuncles (culture positive for mixed flora – gram positive and gram cocci as well as methicillin sensitive and resistant staph aureus.

Tumor response

In this study all patients were evaluable for response by RECIST criteria. Of the eighteen patients studied, sixteen patients experienced progressive disease during the first two cycles. One patient with adrenocortical cancer (cohort 4) and another with renal cell cancer (cohort 2) experienced 4.3 and 5.1 months of stable disease while on protocol therapy.

Discussion

Both COX-2 inhibitors and ubiquitin-proteasome pathway inhibitors down-regulate NF-κB. Combining these two classes of agents is an interesting opportunity to investigate potential clinical synergy with a combination of drugs not known to have overlapping toxicities.

This is the first phase I study to combine bortezomib and celecoxib in patients with advanced solid tumors. The primary endpoint of this study was to determine the maximal tolerated doses of these agents when taken in combination. No dose-limiting toxicities were observed during the first cycle of treatment at any dose-level and cumulative toxicities were manageable.

In our phase I study, two patients with previously progressive disease experienced stable disease on therapy. A patient with metastatic adrenocortical cancer, previously intolerant of mitotane, achieved stable disease for 4.3 months until progression. A second patient with papillary renal cell carcinoma achieved stable disease for 5.1 months. This patient had documented tumor progression on multi-agent chemotherapy prior to enrolling on this trial.

Interesting new data have been reported for celecoxib and bortezomib since our study began. Celecoxib has been shown to potentially have single-agent activity in men with PSA recurrence after local prostate cancer therapy [28]. Also, patients with non-small cell lung cancer receiving single-agent bortezomib recently reported an 8% response rate [29]. Similarly, a phase II trial of patients with metastatic renal cell carcinoma reported a response rate of 11% and 38% of patients reported stable disease with bortezomib [30]. Conversely, no tumor responses were seen in recent studies of bortezomib in metastatic melanoma, breast cancer, or colorectal cancer [3133].

Conclusion

In conclusion, the combination of bortezomib and celecoxib was well tolerated across the dose levels investigated. No dose-limiting toxicities were witnessed and we plan to proceed with dose level six (bortezomib 1.3 mg/m2 days 1, 4, 8, and 11 repeated every 21 days in combination with celecoxib 400 mg orally twice daily) in a subsequent phase II study.

Declarations

Authors’ Affiliations

(1)
Hollings Cancer Center, Medical University of South Carolina

References

  1. Nandi D, Tahiliani P, Kumar A, Chandu D: The ubiquitin-proteasome system. J Biosci. 2006, 31 (1): 137-155. 10.1007/BF02705243.View ArticlePubMedGoogle Scholar
  2. Ciechanover A, Iwai K: The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life. 2004, 56 (4): 193-201.View ArticlePubMedGoogle Scholar
  3. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993, 362 (6423): 847-849. 10.1038/362847a0.View ArticlePubMedGoogle Scholar
  4. King RW, Deshaies RJ, Peters JM, Kirschner MW: How proteolysis drives the cell cycle. Science. 1996, 274 (5293): 1652-1659. 10.1126/science.274.5293.1652.View ArticlePubMedGoogle Scholar
  5. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995, 2 (5): 493-506. 10.1016/1074-7613(95)90030-6.View ArticlePubMedGoogle Scholar
  6. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW: Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53 (6): 1322-1327.PubMedGoogle Scholar
  7. Funkhouser EM, Sharp GB: Aspirin and reduced risk of esophageal carcinoma. Cancer. 1995, 76 (7): 1116-1119. 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
  8. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S: Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 2000, 9 (1): 119-123.PubMedGoogle Scholar
  9. Jung TT, Berlinger NT, Juhn SK: Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope. 1985, 95 (3): 307-312. 10.1288/00005537-198503000-00014.View ArticlePubMedGoogle Scholar
  10. Castonguay A, Rioux N: Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis. 1997, 18 (3): 491-496. 10.1093/carcin/18.3.491.View ArticlePubMedGoogle Scholar
  11. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer research. 2000, 60 (8): 2101-2103.PubMedGoogle Scholar
  12. Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology (Cambridge, Mass. 1996, 7 (2): 203-205.View ArticleGoogle Scholar
  13. McCormick DL, Moon RC: Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br J Cancer. 1983, 48 (6): 859-861.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994, 121 (4): 241-246.View ArticlePubMedGoogle Scholar
  15. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993, 328 (18): 1313-1316. 10.1056/NEJM199305063281805.View ArticlePubMedGoogle Scholar
  16. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996, 56 (11): 2556-2560.PubMedGoogle Scholar
  17. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55 (17): 3785-3789.PubMedGoogle Scholar
  18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93 (5): 705-716. 10.1016/S0092-8674(00)81433-6.View ArticlePubMedGoogle Scholar
  19. Leahy KM, Koki AT, Masferrer JL: Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000, 7 (11): 1163-1170.View ArticlePubMedGoogle Scholar
  20. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004, 23 (57): 9247-9258.PubMedGoogle Scholar
  21. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003, 9 (3): 1136-1144.PubMedGoogle Scholar
  22. Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y, Imai K: Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res. 2005, 11 (14): 5248-5256. 10.1158/1078-0432.CCR-05-0085.View ArticlePubMedGoogle Scholar
  23. Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK, Kim JW, Surh YJ, Bang YJ, Song YS: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. Journal of cancer research and clinical oncology. 2004, 130 (9): 551-560. 10.1007/s00432-004-0567-6.View ArticlePubMedGoogle Scholar
  24. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002, 8 (8): 2505-2511.PubMedGoogle Scholar
  25. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004, 22 (11): 2108-2121. 10.1200/JCO.2004.02.106.View ArticlePubMedGoogle Scholar
  26. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005, 352 (11): 1071-1080. 10.1056/NEJMoa050405.View ArticlePubMedGoogle Scholar
  27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093/jnci/92.3.205.View ArticlePubMedGoogle Scholar
  28. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E: Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006, 12 (7 Pt 1): 2172-2177. 10.1158/1078-0432.CCR-05-2067.View ArticlePubMedGoogle Scholar
  29. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006, 24 (31): 5025-5033. 10.1200/JCO.2006.06.1853.View ArticlePubMedGoogle Scholar
  30. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004, 22 (18): 3720-3725. 10.1200/JCO.2004.10.155.View ArticlePubMedGoogle Scholar
  31. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C: A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005, 103 (12): 2584-2589. 10.1002/cncr.21108.View ArticlePubMedGoogle Scholar
  32. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A: A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005, 11 (15): 5526-5533. 10.1158/1078-0432.CCR-05-0081.View ArticlePubMedGoogle Scholar
  33. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M: Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006, 17 (5): 813-817. 10.1093/annonc/mdj131.View ArticlePubMedGoogle Scholar
  34. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/221/prepub

Copyright

© Hayslip et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement